Glycemic targets and management should be individualized to the person rather than a one-size-fits-all strategy. To prevent both microvascular and macrovascular complications of diabetes, there is a strong need to overcome therapeutic inertia and treat patients based on individual needs. HbA1c test, continuous glucose monitoring (CGM) with time in range (TIR) and/or glucose management indicator (GMI), and blood glucose monitoring (BGM) are all used to assess glycemic control. HbA1c is the statistic used in clinical studies to demonstrate the advantages of better glycemic management. Individual glucose monitoring is a valuable tool for diabetes self-management, which includes meals, physical activity, and prescription adjustments, especially for insulin users. CGM provides an increasingly essential role in managing the effectiveness and safety of therapy in many patients with type 1 diabetes and certain people with type 2 diabetes. Individuals on various insulin treatment schemes might benefit from CGM by improving glucose control, reducing hypoglycemia, and increasing self-efficacy